Consensus Dr. Reddy's Laboratories Limited

Stocks

DRREDDY

INE089A01031

Pharmaceuticals

Market Closed - Bombay S.E. Other stock markets 06:00:51 2026-07-20 EDT			5-day change	1st Jan Change
1,223.30 ^INR	+1.03%		-1.78%	-3.76%

07-20	Aspen Pharmacare wins Canada approval for generic Ozempic after Novo patent expiry	RE
07-20	Asian Equities Traded in the US as American Depositary Receipts Rise in Monday Trading	MT

Evolution of the Average Target: Dr. Reddy's Laboratories Limited

Evolution of the Target Price: Dr. Reddy's Laboratories Limited

Changes in Analyst Recommendations: Dr. Reddy's Laboratories Limited

e7.ASlgs5K3iynAGeAEJVs3HC4Q_UxNoimpn5tCp5a2HXU.V10Q26Pns2P1adZTS2wOeWtcvx8O52fY6PM76vXaKwNVRjXe2v_eULJzrQ~22a479c4f526c03d309ab97f835eb02d

Analysts' recommendations: Dr. Reddy's Laboratories Limited

07-10	Elara Securities India Downgrades Dr. Reddy's Laboratories to Reduce From Accumulate; Price Target is INR1,283	MT
06-22	Nomura Adjusts Dr. Reddy's Laboratories' Price Target to INR1,740 From INR1,600, Keeps at Buy	MT
01-23	YES Research Upgrades Dr. Reddy's Laboratories to Add from Reduce, Price Target is INR1,340	MT
01-23	Nomura Adjusts Dr. Reddy's Laboratories' Price Target to INR1,600 From INR1,580, Keeps at Buy	MT
01-22	ICICI Securities Upgrades Dr. Reddy's Laboratories to Add from Hold, Price Target is INR1,300	MT
01-22	Jefferies Adjusts Dr. Reddy's Laboratories' Price Target to INR1,040 from INR1,100, Keeps at Underperform	MT
25-10-30	Nomura Adjusts Dr. Reddy's Laboratories' Price Target to INR1,580 From INR1,650, Keeps at Buy	MT
25-10-27	Choice Equity Upgrades Dr. Reddy's Laboratories to Add from Reduce; Price Target is INR1,380	MT
25-10-27	Nomura Adjusts Dr. Reddy's Laboratories' Price Target to INR1,650 From INR1,660, Keeps at Buy	MT
25-10-27	Jefferies Adjusts Dr. Reddy's Laboratories' Price Target to INR1,130 From INR1,100, Keeps at Underperform	MT
25-10-13	BNP Paribas Exane Initiates Dr. Reddy's Laboratories at Neutral With $13.18 Price Target	MT
25-07-25	Nomura Adjusts Dr. Reddy's Laboratories' Price Target to INR1,660 From INR1,575, Keeps at Buy	MT
25-07-24	Jefferies Adjusts Dr. Reddy's Laboratories' Price Target to INR1,100 From INR1,010, Keeps at Underperform	MT
25-05-12	Jefferies Adjusts Dr. Reddy's Laboratories' Price Target to INR1,010 from INR1,170, Keeps at Underperform	MT
25-01-27	Nomura Adjusts Dr. Reddy's Laboratories' Price Target to INR1,575 From INR1,500, Keeps at Buy	MT
25-01-24	Jefferies Adjusts Dr. Reddy's Laboratories' Price Target to INR1,170 From INR1,210, Keeps at Underperform	MT
24-12-20	Nomura Upgrades Dr. Reddy's Laboratories to Buy From Neutral, Cuts Price Target to 1,500 Indian Rupees From 6,499 Indian Rupees	MT
24-11-06	Jefferies Adjusts Dr. Reddy's Laboratories' Price Target to INR1,130 From INR1,120, Keeps at Underperform	MT
24-07-29	Jefferies Adjusts Dr. Reddy's Laboratories' Price Target to INR5,600 From INR5,010, Keeps at Underperform	MT
24-05-08	Jefferies Adjusts Dr. Reddy’s Laboratories’ Price Target to INR5,010 From INR5,040, Keeps at Underperform	MT
24-01-29	Barclays Adjusts Price Target on Dr. Reddy's Laboratories to $80 From $75, Keeps Overweight Rating	MT
23-10-30	Jefferies Adjusts Dr. Reddy’s Laboratories’ Price Target to INR6,250 From INR6,330, Keeps at Buy	MT
23-07-27	Jefferies Adjusts Dr. Reddy Laboratories’ to INR6,300 From INR5,600, Keeps at Buy	MT
23-06-01	Barclays Adjusts Price Target on Dr. Reddy's Laboratories to $70 From $67, Maintains Overweight Rating	MT
23-01-30	Nomura Adjusts Dr Reddy's Laboratories' Price Target to INR5,161 From INR5,552, Keeps at Buy	MT

More recommendations

Sector Comparison:

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	DR. REDDY'S LABORATORIES LIMITED					+10.36%
	ELI LILLY AND COMPANY					+7.74%
	JOHNSON & JOHNSON					+6.68%
	ABBVIE INC.					+4.75%
	ROCHE HOLDING AG					+7.49%
	NOVARTIS AG					-1.48%
	ASTRAZENECA PLC					+25.2%
	NOVO NORDISK A/S					-4.34%
	AMGEN INC.					-2.64%
	GILEAD SCIENCES, INC.					+17.89%
	Average					+7.16%
	Weighted average by Cap.					+6.87%